Aims To investigate inhibition of recombinant CYP2C8 by: (i) prototypic CYP isoform selective inhibitors (ii) imidazole/triazole antifungal agents (known inhibitors of CYP), and (iii) certain CYP3A substrates (given the apparent overlapping substrate specificity of CYP2C8 and CYP3A).Methods CYP2C8...
Aims To investigate inhibition of recombinant CYP2C8 by: (i) prototypic CYP isoform selective inhibitors (ii) imidazole/triazole antifungal agents (known inhibitors of CYP), and (iii) certain CYP3A substrates (given the apparent overlapping substrate specificity of CYP2C8 and CYP3A).Methods CYP2C8 and NADPH‐cytochrome P450 oxidoreductase were coexpressed in Spodoptera frugiperda (Sf21) cells using the baculovirus expression system. CYP isoform selective inhibitors, imidazole/triazole antifungal agents and CYP3A substrates were screened for their inhibitory effects on CYP2C8‐catalysed torsemide tolylmethylhydroxylation and, where appropriate, the kinetics of inhibition were characterized. The conversion of torsemide to its tolylmethylhydroxy metabolite was measured using an h.p.l.c. procedure.Results At concentrations of the CYP inhibitor ‘probes’ employed for isoform selectivity, only diethyldithiocarbamate and ketoconazole inhibited CYP2C8 by > 10%. Ketoconazole, at an added concentration of 10 µm, inhibited CYP2C8 by 89%. Another imidazole, clotrimazole, also potently inhibited CYP2C8. Ketoconazole and clotrimazole were both noncompetitive inhibitors of CYP2C8 with apparent Ki values of 2.5 µm. The CYP3A substrates amitriptyline, quinine, terfenadine and triazolam caused near complete inhibition (82-91% of control activity) of CYP2C8 at concentrations five‐fold higher than the known CYP3A Km. Kinetic studies with selected CYP3A substrates demonstrated that most inhibited CYP2C8 noncompetitively. Apparent Ki values for midazolam, quinine, terfenadine and triazolam ranged from 5 to 25 µm.Conclusions Inhibition of CYP2C8 occurred at concentrations of ketoconazole and diethyldithiocarbamate normally employed for selective inhibition of CYP3A and CYP2E1, respectively. Some CYP3A substrates have the capacity to inhibit CYP2C8 activity and this may have implications for inhibitory drug interactions in vivo.
Aims To investigate inhibition of recombinant CYP2C8 by: (i) prototypic CYP isoform selective inhibitors (ii) imidazole/triazole antifungal agents (known inhibitors of CYP), and (iii) certain CYP3A substrates (given the apparent overlapping substrate specificity of CYP2C8 and CYP3A).Methods CYP2C8 and NADPH‐cytochrome P450 oxidoreductase were coexpressed in Spodoptera frugiperda (Sf21) cells using the baculovirus expression system. CYP isoform selective inhibitors, imidazole/triazole antifungal agents and CYP3A substrates were screened for their inhibitory effects on CYP2C8‐catalysed torsemide tolylmethylhydroxylation and, where appropriate, the kinetics of inhibition were characterized. The conversion of torsemide to its tolylmethylhydroxy metabolite was measured using an h.p.l.c. procedure.Results At concentrations of the CYP inhibitor ‘probes’ employed for isoform selectivity, only diethyldithiocarbamate and ketoconazole inhibited CYP2C8 by > 10%. Ketoconazole, at an added concentration of 10 µm, inhibited CYP2C8 by 89%. Another imidazole, clotrimazole, also potently inhibited CYP2C8. Ketoconazole and clotrimazole were both noncompetitive inhibitors of CYP2C8 with apparent Ki values of 2.5 µm. The CYP3A substrates amitriptyline, quinine, terfenadine and triazolam caused near complete inhibition (82-91% of control activity) of CYP2C8 at concentrations five‐fold higher than the known CYP3A Km. Kinetic studies with selected CYP3A substrates demonstrated that most inhibited CYP2C8 noncompetitively. Apparent Ki values for midazolam, quinine, terfenadine and triazolam ranged from 5 to 25 µm.Conclusions Inhibition of CYP2C8 occurred at concentrations of ketoconazole and diethyldithiocarbamate normally employed for selective inhibition of CYP3A and CYP2E1, respectively. Some CYP3A substrates have the capacity to inhibit CYP2C8 activity and this may have implications for inhibitory drug interactions in vivo.
참고문헌 (39)
Miners, John O., Birkett, Donald J..
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
British journal of clinical pharmacology,
vol.45,
no.6,
525-538.
Bertilsson, Leif.
Geographical/Interracial Differences in Polymorphic Drug Oxidation : Current State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19.
Clinical pharmacokinetics,
vol.29,
no.3,
192-209.
Coller, J. K., Somogyi, A. A., Bochner, F..
Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4.
Xenobiotica,
vol.29,
no.10,
973-986.
Xu, Zhen‐Hua, Wang, Wei, Zhao, Xue‐Jun, Huang, Song‐Lin, Zhu, Bing, He, Nan, Shu, Yan, Liu, Zhao‐Qian, Zhou, Hong‐Hao.
Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N‐demethylation of sertraline in human liver microsomes.
British journal of clinical pharmacology,
vol.48,
no.3,
416-423.
Baldwin,, Clarke,, Chenery,.
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
British journal of clinical pharmacology,
vol.48,
no.3,
424-432.
M??ck, Wolfgang.
Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions :.
Drugs,
vol.56,
no.suppl1,
15-23.
Cancer Res Rahman A 5543 54 1994 Selective biotransformation of taxol to 6α‐hydroxytaxol by human cytochrome P4502C8
Drug Metab Dispos Yamazaki H 1260 27 1999 Oxidation of troglitazone to a quinone‐type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes
Tracy, Timothy S., Korzekwa, Kenneth R., Gonzalez, Frank J., Wainer, Irving W..
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.
British journal of clinical pharmacology,
vol.47,
no.5,
545-552.
Nadin, Louise, Murray, Michael.
Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes.
Biochemical pharmacology,
vol.58,
no.7,
1201-1208.
Rifkind, Arleen B., Lee, Charis, Chang, Thomas K.H., Waxman, David J..
Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Archives of biochemistry and biophysics,
vol.320,
no.2,
380-389.
ISSX Proc Rees HC 72 14 1999 A novel genetic polymorphism in the cytochrome P450 CYP2C8
10.1016/S0065-7743(08)60744-7
ONG, C. E., MINERS, J. O., BIRKETT, D. J., BHASKER*, C. R..
Baculovirus-mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase : optimization of protein expression.
Xenobiotica,
vol.28,
no.2,
137-152.
Miners, John O., Coulter, Sally, Birkett, Donald J., Goldstein, Joyce A..
Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes :.
Pharmacogenetics,
vol.10,
no.3,
267-270.
Chang, T.K.H., Gonzalez, F.J., Waxman, D.J..
Evaluation of Triacetyloleandomycin, α-Nasymphthoflavone and Diethyldithiocarbamate as Selective Chemical Probes for Inhibition of Human Cytochromes P450.
Archives of biochemistry and biophysics,
vol.311,
no.2,
437-442.
Xenobiotica Ono S 681 26 1996 10.3109/00498259609046742 Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA‐expressed human P450s and human liver microsomes
Cancer Res Harris JW 4026 54 1994 Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
Back, DJ, Tjia, JF.
Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes..
British journal of clinical pharmacology,
vol.32,
no.5,
624-626.
ISSX Proc Gibbs MA 157 12 1997 Differential inhibition of CYP3A4 and CYP3A5 by antifungal agents
Murray, Michael.
Mechanisms of the Inhibition of Cytochrome P 450-Mediated Drug Oxidation by Therapeutic Agents.
Drug metabolism reviews,
vol.18,
no.1,
55-81.
Back, DJ, Tjia, JF, Karbwang, J, Colbert, J.
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines..
British journal of clinical pharmacology,
vol.26,
no.1,
23-29.
MAURICE, Manuelle, EMILIANI, Stephane, DALET‐BELUCHE, Isabelle, DERANCOURT, Jean, LANGE, Reinhard.
Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes.
European journal of biochemistry,
vol.200,
no.2,
511-517.
TASSANEEYAKUL, W., *, D. J. BIRKETT and J. O. MINERS.
Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and nonsteroidal anti-inflammatory agents.
Xenobiotica,
vol.28,
no.3,
293-301.
Mol Pharmacol Kronbach T 89 36 1989 Oxidation of midazolam and triazolam by by human liver cytochrome P450 IIIA4
Zhang, H., Coville, P. F., Walker, R. J., Miners, J. O., Birkett, D. J., Wanwimolruk, S..
Evidence for involvement of human CYP3A in the 3‐hydroxylation of quinine.
British journal of clinical pharmacology,
vol.43,
no.3,
245-252.
Drug Metab Dispos Rodrigues AD 765 23 1995 In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH‐P450 reductase: comparison to human liver microsomes and precision cut tissue slices
J Pharmacol Exp Ther Von Moltke LL 370 276 1996 Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of predicted interaction with ketoconazole
Drug Metab Dispos Fabre G 978 21 1993 Evidence of CYP3A4 mediated N‐deethylation of amiodarone in human liver microsomal fractions
Ghahramani, P., Ellis, S. W., Lennard, M. S., Ramsay, L. E., Tucker, G. T..
Cytochromes P450 mediating the N‐demethylation of amitriptyline.
British journal of clinical pharmacology,
vol.43,
no.2,
137-144.
Drug Metab Dispos Jonsson G 137 23 1995 Budesonide is metabolised by cytochrome P450, 3A (CYP3A) enzymes in human liver.
Transplant Proc Maurer G 19 17 1 1985 Metabolism of cyclosporin
Andersson, T, Miners, JO, Veronese, ME, Birkett, DJ.
Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms..
British journal of clinical pharmacology,
vol.38,
no.2,
131-137.
Drug Metab Dispos Pichard L 711 18 1990 Identification of the rabbit and human cytochromes P450 IIIA as the major enzymes involved in the N‐demethylation of diltiazem
Bargetzi, Mario J, Aoyama, Toshifumi, Gonzalez, Frank J, Meyer, Urs A.
Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.
Clinical pharmacology and therapeutics,
vol.46,
no.5,
521-527.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.